Pharmacogenetics: From Bench to Byte-An Update of Guidelines
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
复制标题
DOI：
10.1038/clpt.2011.34
复制
发表时间：
2011-05-01
影响因子：
6.7
通讯作者：
Guchelaar, H-J
中科院分区：
文献类型：
--
作者：
Swen, J. J.;Nijenhuis, M.;Guchelaar, H-J
目前，很少有指南将药物遗传学测试的结果与具体的治疗建议联系起来。因此，荷兰皇家药学促进协会成立了药物遗传学工作组，目的是制定基于药物遗传学的治疗（剂量）建议。在系统回顾文献后，我们推荐了53种与CYP2D6、CYP2C19、CYP2C9、硫嘌呤- s -甲基转移酶（TPMT）、二氢嘧啶脱氢酶（DPD）、维生素K环氧化物还原酶（VKORC1）、尿嘧啶二磷酸葡萄糖醛基转移酶1A1 （UGT1A1）、HLA-B44、HLA-B*5701、CYP3A5和V Leiden因子（FVL）相关基因编码的药物。
Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).